References
- Appel IM, Kazemier KM, Boos J, . Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia:results from a single agent window study. Leukemia 2008;22:1665–1679.
- Kaspers GJ, Veerman AJ, Pieters R, . In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723–2729.
- Silverman LB, Gelber RD, Dalton VK, . Improved outcome for children with acute lymphoblastic leukemia:results of Dana-Farber Consortium Protocol 91 - 01. Blood 2001;97:1211–1218.
- Asselin BL, Kreissman S, Coppola DJ, . Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21:6–12.
- Asselin BL, Ryan D, Frantz CN, . In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989;49:4363–4368.
- Bussolati O, Belletti S, Uggeri J, . Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res 1995;220:283–291.
- Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia—asparagine synthetase. Biochem Pharmacol 1969;18: 2578–2580.
- Kiriyama Y, Kubota M, Takimoto T, . Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia 1989;3:294–297.
- Appel IM, den Boer ML, Meijerink JP, . Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006;107:4244–4249.
- Fine BM, Kaspers GJ, Ho M, . A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005;65:291–299.
- Holleman A, Cheok MH, den Boer ML, . Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533–542.
- Iwamoto S, Mihara K, Downing JR, . Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049–1057.
- van der Does-van den Berg A, Bartram CR, Basso G, . Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the “BFM Family” Cooperative Group. Med Pediatr Oncol 1992;20: 497–505.
- Rizzari C, Citterio M, Zucchetti M, . A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91: 24–31.
- Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphatic leukaemia—still to be defined? Br J Haematol 2004;125:117–127.
- Riccardi R, Holcenberg JS, Glaubiger DL. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554–4558.
- Fung KL, Liang RH, Chan GC. Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. Leuk Lymphoma 2010;51:515–522.
- Lepage N, McDonald N, Dallaire L, . Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population. Clin Chem 1997;43:2397–2402.
- Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005;44: 367–393.
- Jarrar M, Gaynon PS, Periclou AP, . Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer 2006;47:141–146.
- Panosyan EH, Grigoryan RS, Avaramis IA, . Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 2004;24: 1121–1126.